Journal of Thoracic Oncology

Scope & Guideline

Leading the Charge in Thoracic Malignancy Insights

Introduction

Immerse yourself in the scholarly insights of Journal of Thoracic Oncology with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN1556-0864
PublisherELSEVIER SCIENCE INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 2006 to 2024
AbbreviationJ THORAC ONCOL / J. Thorac. Oncol.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressSTE 800, 230 PARK AVE, NEW YORK, NY 10169

Aims and Scopes

The Journal of Thoracic Oncology focuses on innovative research, clinical studies, and advancements in the field of thoracic oncology, particularly lung cancer and mesothelioma. This journal serves as a platform for disseminating knowledge that can enhance patient care and treatment outcomes.
  1. Lung Cancer Research:
    The journal covers a wide spectrum of lung cancer research, including molecular biology, genetics, treatment outcomes, and clinical trials for various lung cancer subtypes.
  2. Mesothelioma Studies:
    Research related to malignant pleural mesothelioma, including treatment protocols, clinical trials, and epidemiology, is a significant focus area.
  3. Innovative Therapeutics:
    The journal emphasizes studies on novel therapeutic approaches, including targeted therapies, immunotherapies, and combinations thereof, particularly in advanced stages of lung cancer.
  4. Patient Outcomes and Quality of Life:
    Research that investigates the impact of treatments on patient outcomes, including survival rates, quality of life, and health-related quality of life assessments.
  5. Diagnostics and Biomarkers:
    The journal publishes studies on the development and validation of diagnostic tools and biomarkers that aid in early detection and personalized treatment strategies for lung cancer.
  6. Health Disparities and Epidemiology:
    Exploration of health disparities in lung cancer diagnosis and treatment across different demographics and geographic locations.
  7. Radiation Oncology:
    Research focusing on the role of radiotherapy in lung cancer treatment, including techniques, dosimetry, and outcomes related to radiation therapy.
The Journal of Thoracic Oncology has identified several emerging trends and themes that reflect the evolving landscape of lung cancer research and treatment. These trends highlight the journal's commitment to addressing current challenges and advancing knowledge in thoracic oncology.
  1. Precision Medicine and Genomic Targeting:
    There is an increased focus on precision medicine, with studies exploring the genomic landscape of lung cancer and how specific mutations can guide targeted therapies.
  2. Immunotherapy and Combination Therapies:
    Research on immunotherapeutic approaches, particularly combinations of immunotherapy with chemotherapy or targeted therapies, is gaining momentum as a primary treatment strategy.
  3. Real-World Evidence:
    There is a growing trend towards publishing real-world evidence studies that assess treatment patterns, outcomes, and patient demographics outside of clinical trial settings.
  4. Artificial Intelligence in Oncology:
    The application of artificial intelligence and machine learning for predicting treatment outcomes, analyzing imaging data, and enhancing diagnostic accuracy is emerging as a significant theme.
  5. Health Equity and Disparities:
    Research addressing health disparities and the social determinants of health in lung cancer outcomes is increasingly prioritized, reflecting a broader commitment to equitable healthcare.
  6. Patient-Reported Outcomes:
    Studies examining patient-reported outcomes, quality of life, and the psychological impacts of lung cancer treatment are becoming more prevalent, emphasizing patient-centered care.
  7. Liquid Biopsy and Minimal Residual Disease Monitoring:
    The use of liquid biopsy techniques for early detection, monitoring treatment response, and assessing minimal residual disease is a rapidly emerging area of interest.

Declining or Waning

While the Journal of Thoracic Oncology has a strong focus on various aspects of lung cancer and mesothelioma, certain topics have seen a decline in prominence over recent years, potentially reflecting shifts in research priorities or advancements in specific areas.
  1. Traditional Chemotherapy Studies:
    Research focusing solely on traditional chemotherapy regimens has decreased, as there is a growing emphasis on targeted therapies and immunotherapy.
  2. Basic Science without Clinical Correlation:
    Studies that delve into basic science without clear clinical applications or implications are becoming less frequent, as the journal prioritizes translational research.
  3. Single-Institution Studies:
    There is a noticeable decline in single-institution studies, with more emphasis on multi-center trials and studies that provide broader data sets for analysis.
  4. Non-Small Cell Lung Cancer (NSCLC) Generalities:
    General reviews or studies on NSCLC without a specific focus on molecular characteristics, treatment responses, or innovative approaches are less common.
  5. Epidemiological Studies without Intervention:
    Epidemiological studies that do not propose specific interventions or actionable insights are waning, as the journal favors studies that lead to clinical advancements.

Similar Journals

World Journal of Oncology

Transforming oncology through shared knowledge and discovery.
Publisher: ELMER PRESS INCISSN: 1920-4531Frequency: 12 issues/year

The World Journal of Oncology, published by ELMER PRESS INC, is a vibrant platform for disseminating groundbreaking research and advancements in the field of oncology. With its ISSN 1920-4531 and E-ISSN 1920-454X, this journal is dedicated to publishing high-quality studies that enhance our understanding of cancer and its treatment. The journal is recognized for its significant contributions, evidenced by its Q2 classification in both Cancer Research and Oncology categories in 2023, and accolades such as a Scopus rank of #126/404 in Medicine _ Oncology. Catering to the needs of researchers, professionals, and students, the World Journal of Oncology offers an essential resource for the latest scientific insights and clinical practices, ensuring the global oncology community remains informed and engaged. The journal operates under a selective publication model, maintaining rigor in peer review while facilitating knowledge sharing across converged years from 2014 to 2016 and 2020 to 2024, further establishing its importance in the ongoing fight against cancer.

Clinical Medicine Insights-Oncology

Exploring the forefront of clinical oncology.
Publisher: SAGE PUBLICATIONS LTDISSN: Frequency: 1 issue/year

Clinical Medicine Insights-Oncology is a leading journal published by SAGE Publications Ltd, focusing on the interdisciplinary aspects of oncology. With an open access model since 2007, this journal fosters the dissemination of high-quality research and clinical insights that are crucial for advancing knowledge in cancer treatment and management. Based in New Zealand, it aims to bridge gaps in current oncology practices through the publication of innovative studies, case reports, and reviews. With a respectable ranking in Scopus at #264 out of 404 journals in the oncology category and belonging to the Q3 quartile, it positions itself as a valuable resource for oncologists, researchers, and students committed to enhancing patient outcomes. This journal strives to provide a platform for groundbreaking research that can impact clinical practice and inform policy within the field of oncology.

Oncology Letters

Transforming Oncology Knowledge into Clinical Practice
Publisher: SPANDIDOS PUBL LTDISSN: 1792-1074Frequency: 12 issues/year

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

Translational Lung Cancer Research

Elevating the standards of translational oncology research.
Publisher: AME PUBLISHING COMPANYISSN: 2218-6751Frequency: 6 issues/year

Translational Lung Cancer Research is a leading journal dedicated to advancing the field of oncology, particularly focusing on groundbreaking discoveries in lung cancer treatment and management. Published by AME Publishing Company, this journal boasts an impressive Q1 classification in the 2023 Oncology category, reflecting its significant contribution to the scientific community, with an outstanding Scopus rank of #92 out of 404 in Medicine _ Oncology, placing it in the 77th percentile. With its commitment to open access, the journal fosters international collaboration and accessibility, making cutting-edge research available to a wide audience. The scope of Translational Lung Cancer Research encompasses clinical trials, experimental studies, and translational research that bridge the gap between laboratory findings and clinical applications. Researchers, professionals, and students seeking to keep abreast of the latest developments in lung cancer research will find invaluable insights within its pages. For further information, please contact at FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG.

ESMO Open

Leading the way in cancer discovery and collaboration.
Publisher: ELSEVIERISSN: Frequency: 6 issues/year

ESMO Open is a premier open-access journal published by Elsevier, dedicated to advancing research in the fields of cancer and oncology. Since its inception in 2016, the journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals, providing a platform for disseminating high-quality, peer-reviewed research. With an impressive Q1 ranking in both Cancer Research and Oncology based on the 2023 category quartiles, ESMO Open ranks within the top tier of its field, showcasing its commitment to excellence and innovation. The journal’s inclusion in Scopus rankings further emphasizes its significant impact, with remarkable placements in the 88th and 83rd percentiles for Oncology and Cancer Research, respectively. Operating under an open access model, ESMO Open ensures that cutting-edge findings and insights are readily available to the global academic community, fostering collaboration and knowledge-sharing to further enhance the understanding and treatment of cancer.

BRITISH JOURNAL OF CANCER

Elevating the Standards of Cancer Research.
Publisher: SPRINGERNATUREISSN: 0007-0920Frequency: 24 issues/year

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

JTO Clinical and Research Reports

Innovating Solutions in Oncology and Pulmonary Health
Publisher: ELSEVIERISSN: Frequency: 12 issues/year

JTO Clinical and Research Reports is an esteemed open-access journal published by Elsevier, dedicated to advancing knowledge in the fields of Oncology and Pulmonary and Respiratory Medicine. Since its inception in 2020, the journal has rapidly gained recognition, achieving a commendable Q1 ranking in both fields as of 2023, highlighting its significant contribution to high-quality research and clinical practice. With an inclusive global reach, JTO Clinical and Research Reports fosters collaboration by allowing unrestricted access to its content, ensuring that vital research findings can be disseminated widely among researchers, clinicians, and students alike. Located in the United States, and with its editorial base in the Netherlands, this journal not only embraces the mission of open science but also strives to publish impactful studies that address critical challenges in cancer treatment and respiratory health. Through its rigorous peer-review process and commitment to excellence, JTO Clinical and Research Reports aims to be at the forefront of scientific discourse and innovation in these dynamic areas of medicine.

Gynecologic Oncology

Shaping the Future of Gynecologic Oncology
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCEISSN: 0090-8258Frequency: 12 issues/year

Gynecologic Oncology, an esteemed journal published by Academic Press Inc Elsevier Science, stands at the forefront of research in the domains of Obstetrics and Gynecology and Oncology. With an exceptional track record dating from 1972 to 2024, this journal has established itself as a vital resource for scholars and practitioners alike, boasting a remarkable Q1 ranking in both fields as of 2023. Gynecologic Oncology not only ranks #13 out of 209 in Obstetrics and Gynecology and #72 out of 404 in Oncology but also operates within the top percentiles of academic influence, with a 94th percentile in Obstetrics and Gynecology and an 82nd percentile in Oncology on Scopus. Although the journal does not currently offer open access, it remains crucial for disseminating original research, reviews, and advances in the management and treatment of gynecological cancers. Researchers and health professionals will find this journal indispensable for staying informed on the latest advancements and breakthroughs in this vital area of medicine, fostering a deeper understanding and potentially transforming patient care practices.

BREAST

Illuminating the path to better breast health solutions.
Publisher: CHURCHILL LIVINGSTONEISSN: 0960-9776Frequency: 6 issues/year

BREAST is a leading peer-reviewed journal dedicated to advancing knowledge and practice in the fields of cancer research, oncology, and surgery, published by Churchill Livingstone. With an impressive impact factor and a prestigious Q1 ranking in multiple categories including Cancer Research, Medicine, and Surgery, the journal consistently delivers high-quality content that informs and inspires researchers, clinicians, and educators. Since its transition to Open Access in 2020, BREAST has significantly expanded its reach, providing immediate and unrestricted access to pivotal studies and findings in breast health and disease management. With a history dating back to 1992 and converging to 2024, the journal serves as an essential resource for the latest developments and innovative approaches in the clinical and biomedical aspects of breast care. Scholars and professionals alike can explore a wealth of research aimed at improving patient outcomes and fostering scientific dialogue in this vital area of healthcare.

Journal of Cancer

Innovative insights for a cancer-free future.
Publisher: IVYSPRING INT PUBLISSN: 1837-9664Frequency: 12 issues/year

Journal of Cancer is a premier, peer-reviewed academic journal published by IVYSPRING INTERNATIONAL PUBLISHING that focuses on advancing the field of oncology. With an impact factor reflecting its significant contributions, this journal ranks in the 80th percentile of medical journals pertaining to oncology, positioning it at #79 out of 404 in Scopus. Since its inception in 2010, the journal has embraced an Open Access model, ensuring that groundbreaking research reaches a global audience without barriers. Based in Australia, the journal addresses a wide array of topics within cancer research, catering to researchers, healthcare professionals, and students committed to enhancing their understanding of the complexities of cancer. Amidst evolving challenges in oncology, the Journal of Cancer serves as a vital platform for disseminating innovative findings, fostering collaboration, and promoting informed decisions that can lead to improved cancer outcomes worldwide.